The risk of drug resistance during long-acting antimicrobial therapy
View ORCID ProfileAnjalika Nande, View ORCID ProfileAlison L. Hill
doi: https://doi.org/10.1101/2021.07.10.21260044
Anjalika Nande
1Program for Evolutionary Dynamics, Harvard University, Cambridge, MA 02138
2Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218
Alison L. Hill
1Program for Evolutionary Dynamics, Harvard University, Cambridge, MA 02138
2Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218
Article usage
Posted July 14, 2021.
The risk of drug resistance during long-acting antimicrobial therapy
Anjalika Nande, Alison L. Hill
medRxiv 2021.07.10.21260044; doi: https://doi.org/10.1101/2021.07.10.21260044
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11623)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3390)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1013)
- Primary Care Research (410)
- Public and Global Health (6021)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)